The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
309
Treatment Emergent Adverse Events
The study was terminated early so no efficacy analysis was done, safety data are reported.
Time frame: up to 48 weeks
Proportion of Study Participants With Recurrence of Any Mood Episode
Time frame: up to 48 weeks
Time to Recurrence of a Depressive Episode
Time frame: up to 48 weeks
Time to Recurrence of a Manic/Hypomanic or a Mixed Episode
Time frame: up to 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Elan Investigational Site
Birmingham, Alabama, United States
Elan Investigational Site
Glendale, Arizona, United States
Elan Investigational Site
Phoenix, Arizona, United States
Elan Investigational Site
Little Rock, Arkansas, United States
Elan Investigational Site
Little Rock, Arkansas, United States
Elan Investigational Site
Cerritos, California, United States
Elan Investigational Site
Costa Mesa, California, United States
Elan Investigational Site
Escondido, California, United States
Elan Investigational Site
Garden Grove, California, United States
Elan Investigational Site
National City, California, United States
...and 72 more locations